Self-Pay vs Insurance in 2026: The Real Math After TrumpRx

For the last three years, the self-pay vs insurance conversation for GLP-1s has been lopsided. Brand-name list prices above $1,000/month made self-pay unrealistic for most men; insurance coverage was the only viable path, and insurance coverage for weight-loss indications was spotty. That calculation has been upended.

As of February 2026, TrumpRx launched as a direct-to-consumer platform that connects consumers to Lilly and Novo Nordisk discount portals. Current prices on the platform are dramatic: Wegovy and Ozempic starting at $199/month, Zepbound at $299/month, Wegovy pill at $149/month.^1,2 Additional price cuts are projected — administration officials indicated injectable prices would fall to approximately $245/month within 2 years.³

This changes everything. Here's the real math on which path — self-pay, insurance, or a hybrid — makes sense for your specific situation in 2026.

The 2026 pricing landscape

Option	Monthly cost	Who qualifies
Insurance copay (covered plans)	$25–$100	Best price — if your plan covers it
TrumpRx Wegovy pill (low dose)	$149	Anyone, self-pay
TrumpRx Wegovy/Ozempic (low dose)	$199	Anyone, self-pay
Medicare Part D (new 2026 coverage)	$50 copay	Medicare enrollees with obesity + comorbidity
TrumpRx Zepbound (low dose)	$299	Anyone, self-pay
Compounded telehealth (budget)	$150–$250	Anyone; regulatory status varies
Walmart/Costco pharmacy cash	$499	Anyone, in-person pickup
Brand-name at non-TrumpRx pharmacy	$800–$1,400	Self-pay without leveraging discounts

The decision tree

Step 1: Do you have insurance that covers GLP-1s for weight loss?

Call your insurance or check your plan documents. Specifically ask: "Is Wegovy covered on my formulary? What's the prior authorization requirement? What's my copay?"

• Yes, copay under $100: insurance is almost certainly the cheapest path. Use it.
• Yes, but requires prior auth and $100–$300 copay: worth going through the process if you qualify; check whether TrumpRx is cheaper after factoring in your plan's deductible status.
• No coverage, or only for Type 2 diabetes (not weight loss): TrumpRx or compounded is your path.

Step 2: If no insurance coverage, which direct path?

Self-pay options in descending cost order:

1. Compounded through telehealth: $150–$250/month. Cheapest. Regulatory status has shifted; ensure the compounding pharmacy is legitimate and LegitScript-certified.
2. TrumpRx Wegovy pill: $149/month at lowest dose. Brand-name, oral, no needles. Only approved for weight management at labeled doses.
3. TrumpRx Wegovy/Ozempic injection: $199/month. Brand-name, injectable.
4. TrumpRx Zepbound: $299/month. Tirzepatide — typically stronger effect for weight loss.
5. Costco/Walmart direct discount: $499/month. In-person pickup; no telehealth step.

Step 3: HSA/FSA consideration

Whichever path you pick, run the spending through an HSA or FSA if available. At 29% effective tax rate, running $3,000/year through tax-advantaged money saves you approximately $870/year. Over 10 years, that's $8,700 in real savings.

The insurance-is-cheapest case

If your insurance covers Wegovy or Zepbound with a reasonable copay (under $100/month), insurance remains the cheapest path. Here's why:

• Insurance copay of $50/month = $600/year.
• TrumpRx Wegovy = $199/month = $2,388/year.
• Savings with insurance: $1,788/year.

Additionally, insurance-covered prescription costs count toward your deductible and out-of-pocket maximum — TrumpRx purchases often do not.⁴ For men with high-deductible plans and significant annual healthcare spending, this matters.

The insurance-is-worse case

In a growing number of situations, self-pay via TrumpRx or compounded is now cheaper than insurance:

• Plans with high specialty tier copays. If your insurance covers GLP-1s but puts them in a specialty tier with 20% coinsurance on a $1,000 drug = $200/month — more than TrumpRx direct.
• Plans that require prior authorization + step therapy. The process burden alone can exceed the cost savings.
• Plans that exclude weight-loss indications entirely. The entire cost is on you anyway.
• High-deductible plans early in the year. If you haven't hit your deductible, insurance doesn't save you anything yet.

For any of these scenarios, TrumpRx self-pay is probably the better path. Run the numbers on your specific situation.

Medicare in 2026

New in 2026: Medicare Part D began covering Wegovy and Zepbound for beneficiaries with obesity and at least one qualifying comorbidity, with a $50 copay.⁵ This is the first time Medicare has covered GLP-1s for weight loss (previous coverage was for diabetes only).

For men 65+ on Medicare, this is a substantial change. Consult your Part D plan for specific coverage and comorbidity requirements.

The compounded question in 2026

For men prioritizing regulatory safety, brand-name via TrumpRx at $199/month is now cheap enough that the compounded cost advantage (down to $150) may not justify the complexity and risk.

The brand-name quality argument

Apart from cost, brand-name products have advantages:

• Manufacturing consistency verified by FDA.
• Published clinical trial data at specific doses.
• Full cardiovascular outcomes data (SELECT for semaglutide 2.4 mg).
• Clear documentation for HSA/FSA and insurance records.
• No ambiguity about what you're injecting.

In the pre-TrumpRx era, these advantages came at a steep premium. In the post-TrumpRx era, they come at a modest premium — often $50–$100/month over compounded. For many men, that's worth paying.

Decision framework

The hidden cost of insurance (counterintuitive)

A less-discussed issue: some plans have narrow formularies that cover only semaglutide (Wegovy) but not tirzepatide (Zepbound). If tirzepatide is the better match for your biology (many men respond better to the dual-agonist), you may end up on a suboptimal medication just because insurance covers it.

In this case, self-pay on the medication that works best may outperform insurance coverage of the medication that works less well. This is a medical-judgment decision, but worth flagging.

The cash-flow question

Insurance-covered medications: predictable monthly cost, hits deductible.
Self-pay: full cost up front, no deductible contribution.

For high-deductible plan holders, if you're going to hit your deductible anyway from other medical spending, insurance-covered GLP-1 helps you reach the deductible faster — after which everything is cheaper. Self-pay GLP-1 doesn't count toward this.

For men who rarely use their insurance, the deductible argument is mostly moot — self-pay is just self-pay.

What about the oral pill?

The Wegovy pill (oral semaglutide) at $149/month is the cheapest brand-name option in 2026. For some men, this is a great fit:

• Needle-averse patients.
• Travel-heavy professionals (easier to carry than pens).
• Men who've tolerated Rybelsus (oral semaglutide for diabetes) well.

Caveats: oral bioavailability is lower than injection, so higher doses are needed; must be taken on empty stomach with water, 30 minutes before food; harder to adjust dose precisely than with injectable forms. Some clinical evidence suggests weight loss outcomes are modestly smaller at comparable effective doses. For most men, injection remains the primary recommendation — but the pill is now a legitimate alternative.

Walmart and Costco direct

Walmart (Zepbound) and Costco (Wegovy/Ozempic) now offer direct-from-manufacturer programs at $499/month for cash customers.⁴ These are $150–$300 more expensive than TrumpRx for the same medications — usually not the best option unless you want in-person pickup and have specific preferences for these retailers.

The bottom line

The self-pay vs insurance calculation in 2026 is radically different than it was in 2024. TrumpRx at $199–$350/month has made brand-name GLP-1s affordable for self-pay for the first time. Compounded options at $150–$250 remain cheaper but with added regulatory uncertainty.

For most men: check insurance first. If covered under $100 copay, use it. If not, TrumpRx direct-to-consumer at $199/month (Ozempic/Wegovy) or $299/month (Zepbound) is the best self-pay option. Run whichever path through an HSA for tax advantage.

Re-evaluate annually. Prices continue to fall (administration projects $245/month by 2028), insurance formularies change, and new options (orforglipron, oral tirzepatide equivalents) are coming. What's optimal in 2026 may not be optimal in 2028.

The era of "GLP-1s are unaffordable" is ending. The new era's question is "which cost-optimized path fits my situation" — and the answer is increasingly self-pay, HSA-run, at $2,500–$4,000/year rather than $12,000–$16,000/year.